Approaching a cure for nasopharyngeal carcinoma: how close are we from there?
作者信息
Ho-Fun Lee Victor
机构信息
Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Clinical Oncology Medical Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
出版信息
Lancet Reg Health West Pac. 2024 Aug 28;50:101186. doi: 10.1016/j.lanwpc.2024.101186. eCollection 2024 Sep.
Abstract
摘要
相似文献
1
Approaching a cure for nasopharyngeal carcinoma: how close are we from there?鼻咽癌治疗方法的探索：我们离治愈还有多远？
Lancet Reg Health West Pac. 2024 Aug 28;50:101186. doi: 10.1016/j.lanwpc.2024.101186. eCollection 2024 Sep.
2
Nasopharyngeal carcinoma: the Dana-Farber Cancer Institute experience with 24 patients treated with induction chemotherapy and radiotherapy.鼻咽癌：达纳-法伯癌症研究所对24例接受诱导化疗和放疗患者的治疗经验。
Ann Otol Rhinol Laryngol. 1987 Sep-Oct;96(5):608-14. doi: 10.1177/000348948709600525.
3
Evidence of being cured for nasopharyngeal carcinoma: results of a multicenter patient-based study in China.鼻咽癌治愈证据：一项基于中国患者的多中心研究结果
Lancet Reg Health West Pac. 2024 Jul 19;49:101147. doi: 10.1016/j.lanwpc.2024.101147. eCollection 2024 Aug.
4
[Expression of PML in carcinogenesis of laryngocarcinoma and nasopharyngeal carcinoma].[PML在喉癌和鼻咽癌发生中的表达]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007 Feb;21(3):128-31.
5
Nasopharyngeal carcinoma in Ibadan, Nigeria: a clinicopathologic study.尼日利亚伊巴丹的鼻咽癌：一项临床病理研究。
Pan Afr Med J. 2020 Jun 9;36:82. doi: 10.11604/pamj.2020.36.82.19657. eCollection 2020.
6
HMGA2 promotes nasopharyngeal carcinoma progression and is associated with tumor resistance and poor prognosis.HMGA2促进鼻咽癌进展，并与肿瘤耐药性及不良预后相关。
Front Oncol. 2024 Jan 18;13:1271080. doi: 10.3389/fonc.2023.1271080. eCollection 2023.
7
Presence of the latent membrane protein 1 gene in nasopharyngeal swabs from patients with mucosal recurrent nasopharyngeal carcinoma.黏膜复发性鼻咽癌患者鼻咽拭子中潜伏膜蛋白1基因的存在情况。
Cancer. 2003 Dec 1;98(11):2385-92. doi: 10.1002/cncr.11820.
8
Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up.磁共振成像检测鼻咽癌：基于长期随访比较MRI与内镜及内镜活检的诊断准确性
AJNR Am J Neuroradiol. 2015 Dec;36(12):2380-5. doi: 10.3174/ajnr.A4456. Epub 2015 Aug 27.
9
Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7.EB 病毒微小 RNA BART10-3p 通过靶向 ALK7 促进鼻咽癌去分化和增殖。
Exp Biol Med (Maywood). 2021 Dec;246(24):2618-2629. doi: 10.1177/15353702211037261. Epub 2021 Aug 23.
10
Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.格陵兰高危鼻咽癌家族中的爱泼斯坦-巴尔病毒免疫反应
J Med Virol. 2007 Dec;79(12):1877-81. doi: 10.1002/jmv.21014.
本文引用的文献
1
Evidence of being cured for nasopharyngeal carcinoma: results of a multicenter patient-based study in China.鼻咽癌治愈证据：一项基于中国患者的多中心研究结果
Lancet Reg Health West Pac. 2024 Jul 19;49:101147. doi: 10.1016/j.lanwpc.2024.101147. eCollection 2024 Aug.
2
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.中国局部晚期鼻咽癌患者同步诱导放化疗联合或不联合信迪利单抗（CONTINUUM）：一项多中心、开放标签、平行分组、随机、对照、III 期临床试验。
Lancet. 2024 Jun 22;403(10445):2720-2731. doi: 10.1016/S0140-6736(24)00594-4. Epub 2024 May 30.
3
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.特瑞普利单抗联合化疗用于复发或转移性鼻咽癌的随机对照临床研究（JUPITER-02 研究）
JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181.
4
Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling.2020 年 185 个国家和地区的鼻咽癌发病和死亡情况以及 2040 年的预测负担：基于人群的全球流行病学特征描述。
JMIR Public Health Surveill. 2023 Sep 20;9:e49968. doi: 10.2196/49968.
5
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).替雷利珠单抗联合化疗作为复发或转移性鼻咽癌的一线治疗：一项多中心 III 期试验（RATIONALE-309）。
Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4. doi: 10.1016/j.ccell.2023.04.014. Epub 2023 May 18.
6
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.卡瑞利珠单抗联合吉西他滨和顺铂与安慰剂联合吉西他滨和顺铂用于复发或转移性鼻咽癌的一线治疗（CAPTAIN-1st）：一项多中心、随机、双盲、III 期临床试验。
Lancet Oncol. 2021 Aug;22(8):1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23.
7
Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG.调强放疗后鼻咽癌第二原发癌：香港鼻咽癌协作组的全港研究。
Oral Oncol. 2020 Dec;111:105012. doi: 10.1016/j.oraloncology.2020.105012. Epub 2020 Sep 24.
8
Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures.全球癌症结局比较：标准化及与医疗保健支出的关联。
BMC Public Health. 2019 Aug 7;19(1):1065. doi: 10.1186/s12889-019-7384-y.
9
Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).香港调强放疗时代鼻咽癌的治疗结果：3328 例患者报告（HKNPCSG 1301 研究）。
Oral Oncol. 2018 Feb;77:16-21. doi: 10.1016/j.oraloncology.2017.12.004. Epub 2017 Dec 12.
10
Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy.全球鼻咽癌发病模式：放疗可及性与预后的相关性。
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1106-12. doi: 10.1016/j.ijrobp.2015.11.047. Epub 2015 Dec 14.
Zotero 插件